These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39048728)

  • 1. MASCC/ISOO Clinical Practice Statement: Management of salivary gland hypofunction and xerostomia in cancer patients.
    Hong C; Jensen SB; Vissink A; Bonomo P; Santos-Silva AR; Gueiros LA; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):548. PubMed ID: 39048728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MASCC/ISOO Clinical Practice Statement: Clinical assessment of salivary gland hypofunction and xerostomia in cancer patients.
    Hong C; Epstein JB; Jensen SB; Gueiros LA; van Leeuwen SJM; Kandwal A; Vissink A; Elad S
    Support Care Cancer; 2024 Jul; 32(8):551. PubMed ID: 39048727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MASCC/ISOO Clinical Practice Statement: Management of oral manifestations of chronic graft-versus-host-disease.
    Zadik Y; Raber-Durlacher JE; Epstein JB; Majorana A; Laheij A; Bardellini E; Blijlevens N; Elad S
    Support Care Cancer; 2024 Jul; 32(8):546. PubMed ID: 39048807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline.
    Mercadante V; Jensen SB; Smith DK; Bohlke K; Bauman J; Brennan MT; Coppes RP; Jessen N; Malhotra NK; Murphy B; Rosenthal DI; Vissink A; Wu J; Saunders DP; Peterson DE
    J Clin Oncol; 2021 Sep; 39(25):2825-2843. PubMed ID: 34283635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MASCC/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy.
    Villa A; Epstein JB; Yarom N; Hong C; Fulop C; Bossi P; Elad S
    Support Care Cancer; 2024 Jul; 32(8):549. PubMed ID: 39048808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.
    Nieuw Amerongen AV; Veerman EC
    Support Care Cancer; 2003 Apr; 11(4):226-31. PubMed ID: 12673460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MASCC/ISOO Clinical Practice Statement: The risk of secondary oral cancer following hematopoietic cell transplantation.
    Raber-Durlacher JE; Treister NS; Zadik Y; Dean DR; Miranda-Silva W; Fregnani ER; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):545. PubMed ID: 39048762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MASCC/ISOO clinical practice statement: Current understanding on controversies in basic oral care in hemato-oncology and hematopoietic cell transplantation.
    Raber-Durlacher JE; Zadik Y; Treister NS; Stempler N; Bruno JS; Epstein JB; Elad S
    Support Care Cancer; 2024 Jul; 32(8):550. PubMed ID: 39048882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
    Riley P; Glenny AM; Hua F; Worthington HV
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012744. PubMed ID: 28759701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary Gland Hypofunction and Xerostomia in Head and Neck Radiation Patients.
    Jensen SB; Vissink A; Limesand KH; Reyland ME
    J Natl Cancer Inst Monogr; 2019 Aug; 2019(53):. PubMed ID: 31425600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.
    Jensen SB; Pedersen AM; Vissink A; Andersen E; Brown CG; Davies AN; Dutilh J; Fulton JS; Jankovic L; Lopes NN; Mello AL; Muniz LV; Murdoch-Kinch CA; Nair RG; Napeñas JJ; Nogueira-Rodrigues A; Saunders D; Stirling B; von Bültzingslöwen I; Weikel DS; Elting LS; Spijkervet FK; Brennan MT; ; ;
    Support Care Cancer; 2010 Aug; 18(8):1061-79. PubMed ID: 20333412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.
    Jensen SB; Pedersen AM; Vissink A; Andersen E; Brown CG; Davies AN; Dutilh J; Fulton JS; Jankovic L; Lopes NN; Mello AL; Muniz LV; Murdoch-Kinch CA; Nair RG; Napeñas JJ; Nogueira-Rodrigues A; Saunders D; Stirling B; von Bültzingslöwen I; Weikel DS; Elting LS; Spijkervet FK; Brennan MT;
    Support Care Cancer; 2010 Aug; 18(8):1039-60. PubMed ID: 20237805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs.
    Plemons JM; Al-Hashimi I; Marek CL;
    J Am Dent Assoc; 2014 Aug; 145(8):867-73. PubMed ID: 25082939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and management of dry mouth and its complications in rheumatology practice.
    Khavandgar Z; Warner BM; Baer AN
    Expert Rev Clin Immunol; 2024; 20(1):1-19. PubMed ID: 37823475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.
    Vissink A; Mitchell JB; Baum BJ; Limesand KH; Jensen SB; Fox PC; Elting LS; Langendijk JA; Coppes RP; Reyland ME
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):983-91. PubMed ID: 20970030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xerostomia and hypofunction of the salivary glands in cancer therapy.
    Jensen SB; Pedersen AM; Reibel J; Nauntofte B
    Support Care Cancer; 2003 Apr; 11(4):207-25. PubMed ID: 12673459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xerostomia/Salivary Gland Hypofunction: Diagnosis and Management.
    Zunt SL
    Compend Contin Educ Dent; 2018 Jun; 39(6):365-369; quiz 371. PubMed ID: 29847962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. World Workshop on Oral Medicine VIII: Development of a core outcome set for dry mouth: a systematic review of outcome domains for salivary hypofunction.
    Simms ML; Kuten-Shorrer M; Wiriyakijja P; Niklander SE; Santos-Silva AR; Sankar V; Kerr AR; Jensen SB; Riordain RN; Delli K; Villa A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2023 Jun; 135(6):804-826. PubMed ID: 37183064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of xerostomia and salivary gland hypofunction in a cohort of HIV-positive and at-risk women.
    Navazesh M; Mulligan R; Komaroff E; Redford M; Greenspan D; Phelan J
    J Dent Res; 2000 Jul; 79(7):1502-7. PubMed ID: 11005735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of xerostomia and salivary gland hypofunction.
    Ram S; Kumar S; Navazesh M
    J Calif Dent Assoc; 2011 Sep; 39(9):656-9. PubMed ID: 22034800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.